Myobloc Shortage Update: What Patients Need to Know in 2026

If you depend on Myobloc (rimabotulinumtoxinB) to manage cervical dystonia or chronic sialorrhea, staying informed about its availability is important. Here's the latest on Myobloc's supply status in 2026 — and what you should know if you're having trouble filling your prescription.

Current Status: Is Myobloc in Shortage in 2026?

As of 2026, Myobloc is not listed on the FDA Drug Shortages Database as an active shortage. The drug continues to be manufactured by Solstice Neurosciences (a Supernus Pharmaceuticals subsidiary) and distributed through specialty pharmaceutical channels in the United States.

However, "not in shortage" does not mean "easy to get." Myobloc is a brand-only specialty injectable with a small patient population, cold chain requirements, and virtually no presence at retail pharmacies. Patients routinely report difficulty obtaining it — not because of a manufacturing disruption, but because of structural access barriers that have been present throughout its history.

Why Myobloc Access Has Always Been Challenging

Several factors have historically made Myobloc difficult to access, even when supply is intact:

Brand-only medication: There is no generic version of rimabotulinumtoxinB. All patients must obtain the brand-name product, which is costly and stocked only by specialty distributors.

Not covered by Medicare: Myobloc is currently not covered by any Medicare plans, significantly limiting access for older adults.

Step therapy requirements: Most commercial insurers require patients to try and fail Botox, Dysport, and/or Xeomin before authorizing Myobloc — adding months to the process for new patients.

Cold chain requirements: Myobloc requires refrigeration at 36°F–46°F and must not be frozen. Not all pharmacies have the infrastructure to stock it properly.

Small patient population: Myobloc is primarily used by patients with type A botulinum toxin resistance. This is a relatively small subset of the already-small cervical dystonia population, so many pharmacies don't stock it routinely.

What Should You Do If You Can't Find Myobloc?

If you're having trouble obtaining Myobloc, here are concrete steps to take:

Contact your prescriber's office. Many neurologists who prescribe Myobloc stock it in-office. If your doctor's office administers the injection, they may already have it — or know exactly where to get it.

Call specialty pharmacies. Accredo, CVS Specialty, and Walgreens Specialty are among the pharmacy networks that may carry Myobloc.

Use medfinder. medfinder calls pharmacies near you to check who has Myobloc available, then texts you the results. This saves significant time vs. calling around yourself.

Contact Myobloc patient support. Call 1-888-461-2255. Solstice Neurosciences may be able to direct you to distributors in your area.

Ask about the copay program. Eligible commercially insured patients may pay $0 for medication and administrative services up to $4,000 per year through the manufacturer's copay program.

What If I Have to Miss a Myobloc Treatment Cycle?

Missing a scheduled Myobloc injection can mean a return of cervical dystonia symptoms — painful involuntary neck contractions, abnormal head posture, and significant discomfort. For sialorrhea patients, drooling may worsen. If you anticipate a gap in treatment, notify your neurologist as soon as possible. They may be able to adjust your schedule or provide symptomatic management options in the interim.

How to Stay Ahead of Access Issues

Because Myobloc effects last 3–4 months, most patients are on a predictable injection cycle. Start working on your next vial procurement 4–6 weeks before your appointment. Keep your prior authorization current (most expire every 6–12 months). For detailed tips, see: How to Find Myobloc in Stock Near You. And when you need help locating it, medfinder is there to do the calling for you.